Apollo News

Home  /  Apollo News
Biotech and Money Life Science Spin-out of the Year

Stevenage, 12 June 2017: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, is pleases to announce that it has been shortlisted as a finalist in the ‘UK Life Science Spin-Out of the Year’ category of the Biotech and Money 2017 Awards.

Apollo was selected as a finalist for the award following its launch last year from AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, University College London and the University of Cambridge. Apollo supports the translation of ground-breaking academic science from within these universities into innovative new drug discovery programmes and potential new medicines for a broad range of diseases. Since its launch, Apollo has approved funding for and launched initial discovery projects across antitrypsin deficiency, retinal degeneration, pulmonary arterial hypertension and the enhancement of autologous and in vivo T-cell therapies.

The winners in each category are determined 50% by this online voting and 50% by a live vote on the night of the Awards dinner, which is held in London on 14 September. Voting is now open.

Read More

First four drug discovery programmes now launched in collaboration with academics at all three partner universities – spanning a variety of disease areas and drug modalities Recruited highly experienced Project Directors with track records of delivering project success within big pharma More than £8.5m committed to projects so far from a total budget of £40m Stevenage, [22 February, 2017]: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies,

Read More
A New Era

A new era of collaboration: why Apollo Therapeutics succeed where other translational funding mechanisms have failed? Ian Tomlinson, Chairman at Apollo Therapeutics, talks to Biotech and Money about the newly formed consortium fund http://www.biotechandmoney.com/blog/2016/05/03/a-new-era-of-collaboration-why-apollo-therapeutics-succeed-where-other-translational-funding-mechanisms-have-failed  

Read More

Stevenage, 14 April 2016 : Apollo Therapeutics (‘Apollo’), the investment fund focussed on driving therapeutic innovation through university collaboration, has appointed Dr Richard Butt as CEO, effective from 23 May 2016.

Read More